Acromegaly  >>  Phase 3
Welcome,         Profile    Billing    Logout  

9 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Acromegaly
2011-004231-31: the effect of the addition of pegvisomant on quality of life and glucose sensitivity in acromegaly patients Pegvisomant-toevoeging bij patiënten met acromegalie: effect op symptomen, kwaliteit van leven en insuline-gevoeligheid

Ongoing
3
60
Europe
pegvisomant, PN-800467, Powder and solvent for cutaneous solution, Somavert
Erasmus University Medical Centre Rotterdam, Erasmus University Medical Centre Rotterdam
acromegaly acromegalie, acromegaly acromegalie, Diseases [C] - Hormonal diseases [C19]
 
 
2014-004386-24: Effect of pegvisomant , GH receptor competitor, using glucose in patients with acromegaly Effetto del pegvisomant, un competitore del recettore dell'ormone GH, sull'utilizzo del glucosio in pazienti con acromegalia

Ongoing
3
16
Europe
somavert, Powder and solvent for solution for injection, SOMAVERT - 10 MG POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 30 FLACONCINI + 30 FLACONCINI 8 ML SOLVENTE USO SOTTOCUTANEO
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II, Pfizer srl
acromegaly acromegalia, Growth Hormone (GH) excess disease malattia dovuta all' eccesso di ormone della crescita (GH), Diseases [C] - Hormonal diseases [C19]
 
 
2015-001292-51: Follow-Up Study in Patients that Participated in the Chiasma Study CH-ACM-01

Ongoing
3
21
Europe
Octreolin,
Chiasma, Inc., Chiasma, Inc
Acromegaly
 
 
OPTIMAL, NCT03252353 / 2017-000737-31: Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

Active, not recruiting
3
56
Europe, Canada, US, RoW
octreotide capsules, MYCAPSSA, Matching placebo, Placebo
Chiasma, Inc.
Acromegaly
06/19
05/22
MERGE, NCT03439709: Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma

Not yet recruiting
3
90
RoW
Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection
Samsung Medical Center
Acromegaly Due to Pituitary Adenoma
06/22
12/22
NCT04076462 / 2019-001191-11: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Completed
3
72
Europe, US, RoW
CAM2029 (octreotide subcutaneous depot), CAM2029, Matching placebo, placebo
Camurus AB
Acromegaly
05/23
05/23
PATHFNDR 1, NCT04837040 / 2020-005431-70: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

Active, not recruiting
3
58
Europe, US, RoW
Paltusotine, CRN00808, Placebo
Crinetics Pharmaceuticals Inc.
Acromegaly
07/23
06/27
PATHFNDR-2, NCT05192382 / 2021-001703-32: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

Active, not recruiting
3
111
Europe, US, RoW
Paltusotine, CRN00808, Placebo
Crinetics Pharmaceuticals Inc.
Acromegaly
01/24
01/28
NCT04125836 / 2019-002190-66: A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Active, not recruiting
3
135
Europe, US, RoW
CAM2029 (octreotide subcutaneous depot), CAM2029
Camurus AB
Acromegaly
06/25
06/25

Download Options